|
WO2007117286A2
|
|
Methods for treating cerebrovascular disease by administering desmethylselegiline
|
|
AU2004202529A1
|
|
Methods and pharmaceutical compositions employing desmethylselegiline enantiomers
|
|
AU2003220016A1
|
|
Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline
|
|
AU9736301A
|
|
Methods and pharmaceutical compositions employing desmethylselegiline enantiomers
|
|
WO0219964A2
|
|
Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
|
|
US6319954B1
|
|
S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
|
|
US6299901B1
|
|
Methods and pharmaceutical compositions employing desmethylselegiline
|
|
EP1063981A1
|
|
Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
|
|
AU9235898A
|
|
Methods and pharmaceutical compositions employing desmethylselegiline
|
|
AU2339797A
|
|
Method for preventing and treating peripheral neuropathy by administering selegiline
|
|
EP0866691A1
|
|
Sublingual and buccal administration of selegiline
|
|
US6348208B1
|
|
Methods and pharmaceutical compositions employing desmethylselegiline
|
|
US6033682A
|
|
S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
|
|
CN1178462A
|
|
Methods and pharmaceutical compostions employing desmethylselegiline
|
|
CA2209892A1
|
|
Methods and pharmaceutical compositions employing desmethylselegiline
|
|
US5242950A
|
|
Treatment of macular degeneration
|
|
HUT55221A
|
|
Process for producing pharmaceutical composition suitable for transdermal administration
|
|
DD283774A5
|
|
Method for producing a means for the treatment of parkinson's disease, alzheimer's disease and depressional diseases and patches
|
|
CA1329132C
|
|
Method for administering the drug deprenyl so as to minimize the danger of side effects
|
